<DOC>
	<DOCNO>NCT03072589</DOCNO>
	<brief_summary>This study evaluate maximum safe dose duration regadenoson ( Lexiscan ) give people lung transplant . Regadenoson give continuous IV infusion . All participant study receive regadenoson infusion begin operate room lung transplant procedure . Participants assign certain dose regadenoson give 12 24 hour period .</brief_summary>
	<brief_title>Study Evaluate Adenosine 2A Receptor Agonist ( Regadenoson ) Patients Undergoing Lung Transplantation</brief_title>
	<detailed_description>Lung transplantation currently one way treat variety serious disease condition emphysema , pulmonary fibrosis , cystic fibrosis . Ischemia Reperfusion Injury ( IRI ) know problem happen first day lung transplant . IRI cause swell lung low level oxygen . The serious type IRI cause transplant lung work properly , even cause death . While new treatment practice put place low chance IRI , still difficult problem overcome lung transplant . Medicines call Adenosine 2A receptor ( A2AR ) study animal IRI many year . Some study suggest use A2AR medicine , chance IRI may lower prevent . Regadenoson A2AR drug .</detailed_description>
	<mesh_term>Adenosine</mesh_term>
	<mesh_term>Regadenoson</mesh_term>
	<criteria>Subjects must undergo bilateral lung transplantation endstage lung disease thus meet criterion list Male female subject , 18 70 year age Subjects must sign study specific informed consent prior study entry Subjects must meet following laboratory value : 1. hemoglobin ≥ 6 g/dL , 2. platelet &gt; 75,000/mcL , 3. aspartate aminotransferase ( AST/SGOT ) / alanine aminotransferase ( ALT /SGPT ) &lt; 2.5 X institutional upper limit normal , 4. serum creatinine &lt; 1.5 mg/dL , 5 . INR &lt; 1.5 , PTT &lt; 40 second Subject require preoperative extracorporeal membrane oxygenation ( ECMO ) Subject second degree ( Mobitz type I II ) thirddegree AV block sinus node dysfunction Subject history bleed diathesis Subject history clinically overt stroke within past 3 year Subject history severe hypertension adequately control antihypertensive medication ( Systolic blood pressure ≥ 200 mmHg and/or Diastolic blood pressure ≥ 110 mmHg ) Subjects receive chronic anticoagulation antiplatelet therapy would preclude surgery ( prophylactic aspirin acceptable ) Subjects history metastatic cancer Subjects history seizure disorder Subjects receive receive within 30 day investigational agent Subjects receive theophylline aminophylline within 12 hour study dose</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>70 Years</maximum_age>
	<verification_date>March 2017</verification_date>
</DOC>